Henry Ford Health

Henry Ford Health Scholarly Commons
Dermatology Articles

Dermatology

10-1-2021

Chemical Peels as Field Therapy for Actinic Keratoses: A
Systematic Review
Angela J. Jiang
Henry Ford Health, ajiang2@hfhs.org

Seaver L. Soon
Peter Rullan
Harold J. Brody
Gary D. Monheit

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/dermatology_articles

Recommended Citation
Jiang AJ, Soon SL, Rullan P, Brody HJ, Monheit GD, and Lee KC. Chemical Peels as Field Therapy for
Actinic Keratoses: A Systematic Review. Dermatol Surg 2021; 47(10):1343-1346.

This Article is brought to you for free and open access by the Dermatology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Dermatology Articles by an authorized administrator of Henry Ford
Health Scholarly Commons.

Authors
Angela J. Jiang, Seaver L. Soon, Peter Rullan, Harold J. Brody, Gary D. Monheit, and Kachiu C. Lee

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
dermatology_articles/609

Review Article

Chemical Peels as Field Therapy for Actinic Keratoses:
A Systematic Review
Angela J. Jiang, MD,* Seaver L. Soon, MD,† Peter Rullan, MD,‡§ Harold J. Brody, MD,║ Gary D. Monheit, MD,{ and
Kachiu C. Lee, MD, MPH#

BACKGROUND Actinic keratoses (AKs) are a common premalignant cutaneous neoplasm and can progress to squamous
cell carcinoma. A variety of treatment options are available for field therapy of diffuse AKs.
OBJECTIVE This review systematically analyzes the use of chemical peels for treatment of AKs.
MATERIALS AND METHODS A systematic review of PubMed was performed searching from 1946 to March 2020 to
identify the literature on chemical peels for AKs.
RESULTS Of the 151 articles identified, 5 met inclusion criteria for review. Four of the reviewed articles demonstrated the
efficacy of chemical peels in reducing AK count and minimal adverse effects. In some studies, chemical peels exhibited
potential to prevent additional AK formation and development of keratinocyte carcinomas.
CONCLUSION Chemical peels are an efficacious and affordable treatment option for field treatment of AKs. With
improved patient tolerance and adherence, chemical peels are an attractive option for field therapy of AKs for both
dermatologists and patients.

A

ctinic keratoses (AKs) are premalignant cutaneous
lesions, typically presenting on sun-exposed sites
such as the face, scalp, and extremities.1 They are
characterized histologically by dysplastic keratinocytes,
with potential progression to squamous cell carcinoma
(SCC), and thus, early detection and treatment are paramount.2,3 A 2012 Cochrane Review concluded the most
effective, evidence-based treatments for AKs include cryotherapy, diclofenac, 5-fluorouracil (5-FU), imiquimod,
ingenol mebutate, laser resurfacing, trichloroacetic acid
chemical peel, aminolevulinic acid photodynamic therapy
(ALA-PDT), and methyl aminolevulinate PDT.4
The choice of field therapy for diffuse AK depends on a
variety of factors, including patient compliance, cost,
tolerance for clinical recovery or “downtime,” and efficacy.
Although most dermatologists agree on the importance of
field treatment, cryotherapy still remains the standard of
care for treatment of AKs. In a survey of over 400 physicians
in 8 countries, 90% of physicians prescribe the treatment
requiring the shortest duration of application and the
highest rate of patient compliance.5 Therefore, an in-office,
single visit procedure may be preferred by patients and
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physicians alike when compared with a prolonged topical
therapy.
Chemical peels are indicated in the management of
extensive, confluent AKs with the goal of replacing atypical
keratinocytes with the normal epidermis and decreasing the
rate of AK recurrence over large surface areas efficiently.6,7
Chemical peels offer a one-time treatment for patients
which circumvents the issue of patient compliance, required
by topical therapies. Patients report preference for the
tolerability of treatment with chemical peels and the shorter
downtime compared with other field treatments.8 This
article systematically evaluates the literature on the safety
and efficacy of chemical peels for treatment of diffuse AKs.

Methods
The National Library of Medicine’s PubMed database was
queried to identify studies on chemicals peels for treatment
of AKs using the search terms “chemical peel,” “chemexfoliation,” “chemabrasion,” “actinic keratosis,” “actinic
damage,” “keratinocyte carcinoma,” “squamous cell carcinoma,” and “basal cell carcinoma.” All randomized and
nonrandomized trials, cohort studies, case reports, and case
series in English language were included with a publication
date range from 1946 to March 18, 2020. Inclusion criteria
also required studies to report pre-treatment and posttreatment AK counts. References from the retrieved articles
were also reviewed for inclusion.
Articles were considered for inclusion based on the title
and abstract.

Results
A total of 151 articles were retrieved, of which 146 were
excluded. Five articles were identified for further review. Of
www.dermatologicsurgery.org
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the 5 articles, one article investigated the use of glycolic acid
peels,9 2 articles studied combination Jessner’s and 35%
trichloroacetic acid (TCA) peels,10,11 and 2 articles studied
TCA peels (Table 1).12

peel was applied until a faint frost was attained. These
patients were followed for one year and re-evaluated
again at 32 months, which was published in a subsequent
study.10,11

Study Design

Trichloroacetic Acid Peels

Glycolic Acid Peels
The efficacy of glycolic acid peels for the treatment of AKs
was studied in a split-face study with 18 patients.9 Glycolic
acid was applied on the skin for 2 minutes and neutralized
with water for 2 minutes. A thin layer of 5-FU solution was
then applied to one side of the face. This regimen was
performed weekly for 8 treatments.

Jessner’s and 35% Trichloroacetic
Acid Peels

Lawrence and colleagues10 compared the efficacy of
Jessner’s and 35% TCA peel compared with 5-FU twice
daily for 3 weeks in a split-face study. The combination

Two studies investigated the efficacy of TCA peels
compared with other field treatments.8,12 In the study by
Hantash and colleagues, 27 patients were randomized to 1
of 3 treatment arms: carbon dioxide laser resurfacing, 30%
TCA peel, or 5-FU twice daily application for 3 weeks.
Patients who received carbon dioxide laser received 2
passes, the first pass at 6 W and second pass at 5 W. For the
chemical peel arm, 30% TCA was applied until a Level 2
frost was noted. AK count was performed 3 months after
treatment, and patients were followed for up to 5 years to
measure the incidence of new KCs.
Thirty-five percent TCA was also compared with ALAPDT in 28 patients.12 Thirty-five percent TCA was applied
until a level 1 frost was achieved. 20% ALA was applied

TABLE 1. Studies Included in Systematic Review of Chemical Peels for Treatment of Actinic Keratosis

Author

Year Study Type

Chemical
Peel

Marrero et al.9 N
5 18

1998 Prospective,
split-face

70% glycolic
acid + 5-FU

Intervention

Glycolic acid peel 2-minute contact 19.7%*
alone weekly 3 8 until neutralization
treatments
Glycolic + 5-FU
weekly 3 8
treatments

Lawrence et al.10
N 5 15

11

1995 Prospective,
split-face

Witheiler et al. N 1997 Prospective,
split-face
5 15 (analysis
was done in 8)
12

Holzer et al.
28

Follow-Up
Period
6 mo

2-minute contact
and one-time
application of 5FU solution

91.9%*

Jessner’s
Jessner’s + 35%
solution +35% TCA
TCA
5-FU

Level 1 frost

75%

BID 3 3 weeks

75%

Jessner’s + 35%
Jessner’s
solution +35% TCA
TCA
5-FU

Level 1 frost

78%*

BID 3 3 weeks

79%*

TCA

Level 1 frost

48 6 35%*

ALA PDT

4-hour incubation
with Tegaderm
followed by redlight PDT

73 6 29%*

5-FU

BID 3 3 weeks

83 6 12.5%* 3 months (AKs)

TCA

Level 2 frost

89 6 6.6%*

CO2

2 passes, first
pass at 6W and
second pass at
5W

N 5 2016 Randomized 35% TCA
prospective

Hantash et al.8 N
5 27

Application

Mean
Reduction
6SD

2006 Randomized 30% TCA
prospective

12 mo

32 mo

12 mo

5 years
(keratinocyte
92 6 10.3%*
carcinomas)

* p , 0.05.
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under occlusion for 4 hours and then irradiated with blue
light photodynamic therapy (PDT) with a dose of 75 J/cm2
at an irradiance of 75 mW/cm2. Patients were reassessed at
months 1, 3, 6, and 12. If more than 50% of baseline count
of AKs were present at any follow-up visit, patients were
retreated with PDT. Five patients who were treated with
TCA required additional treatments with PDT, whereas 2
patients treated with PDT received additional PDT
treatments.

Efficacy
30% TCA peels are associated with comparable reduction
in AKs relative to carbon dioxide laser resurfacing and 5FU.8 Combination Jessner’s and 35% TCA solution
demonstrates an additional benefit in reduction of histologic atypia.10,11 When compared with ALA-PDT, 35%
TCA showed lesser reduction of AKs; however, the 35%
TCA peel was applied to a more superficial frost (Level 1)
compared with the 30% TCA peel (Level 2).8,12

Adverse Effects
Overall, chemical peels are well tolerated: One study showed
no side effects, such as postinflammatory hyperpigmentation
or scarring, after chemical peels,8 whereas others reported
transient erythema and discomfort after application.9,10 By
contrast, 2 patients aborted laser treatment because of
intolerance of the procedure.8 5-FU as monotherapy was
associated with pain, pruritus, inflammation, erythema, and,
often, erosions.8,10,11 Combination treatment 5-FU with
chemical peels such as glycolic and Jessner’s peels, however,
may minimize these typical side effects of 5-FU when used
before a 5-FU treatment course.9,13 Subjectively, studies
reported that patients preferred chemical peel resurfacing to
5-FU because of its single application, fewer adverse effects,
and rapid healing time.8,10
When compared with chemical peels, one study reported
that PDT treatment was associated with comparatively greater
pain, persistent erythema, and pustular reaction.12 The same
study also reported scarring in 6 patients (21% of enrolled
patients) treated with 35% TCA.12 Of the 6 patients with
reported scarring, Holzer and colleagues12 graded overall
cosmetic outcome as excellent or good, with mild to moderate
erythema or change in pigmentation, in all but 2 patients.
Cosmetic outcomes that were graded as fair or poor were
defined by the presence of slight to moderate or extensive
scarring, respectively. Although 6 patients were reported to
have scarring, there is discordance between the reported
scarring and the overall graded cosmetic outcome. Limited
information was provided in the study regarding other
possible contributors to scarring such as infection or
exogenous trauma. Moreover, additional PDT treatments
for patients who had initially received a TCA peel could have
potentially contributed to less favorable cosmetic outcomes.
Despite variation in adverse effects observed, the studies
with mild or no side effects observed also demonstrated
improved clearance of AKs compared with the one study
with reported scarring.8–12
Chemical Peeling for AK Review • Jiang et al

Prevention of Additional
Actinic Keratoses
Although many lesion-directed and field treatments effectively treat AKs, field treatments have demonstrated variable effectiveness in prophylaxis against recurrent AKs or
new AK development.14 Combination Jessner’s with 35%
TCA peel demonstrated reduction in AK recurrence
between 12 and 32 months after one treatment.11 Witheiler
and colleagues11 observed that AK counts increased after 32
months; however, background atypia and dysmaturation
remained improved after 32 months.

Prevention of Keratinocyte Carcinomas
Chemical peels may have an effect on long-term keratinocyte
carcinoma prevention. At 5-year follow-up, the rate of
keratinocyte carcinoma development in patients treated with
TCA peels was 3.75 to 5.25 times lower compared with 5-FU
and carbon dioxide laser resurfacing. One SCC in situ occurred
in the TCA arm, compared with 5 SCCs and 3 BCCs in the 5FU and carbon dioxide laser resurfacing arm, respectively.8
Although limited by the small sample size, the TCA peel arm
showed a statistically significant 40-fold decrease in the rate of
keratinocyte carcinoma development compared with the
control group.8 Of the 4 treatment arms studied, the patients
within the TCA group had higher AK counts and oldest age
compared with the other treatment arms.8 Overall, the
demographic differences between the treatment arms in this
study did not meet statistical significance.8 These results are
similar to a split-faced study that showed development of one
SCC after treatment with combination Jessner’s and TCA,
whereas 2 SCCs developed after treatment with 5-FU.11

Discussion
Because of their high prevalence, potential for malignant
transformation, and substantial economic burden, AKs
present a major health care concern. In 2015, more than
35.6 million AK lesions were treated, compared with 29.7
million lesions treated in 2007.13 A review of Veterans
Health Administration data in 2012 showed greater than
$200 million expenditure in treatment of AKs and greater
than $356 million expenditure on treatment of both
keratinocyte carcinomas and AKs.14 Chemical peels are
an effective, safe, and well-tolerated therapy for field
treatment of AKs. Furthermore, field treatment of AKs in
high-risk patients with chemical peels may prevent keratinocyte carcinomas.
Although targeted treatment of solitary AKs can be
accomplished easily with cryotherapy, field treatment of
AKs uses a variety of modalities. Of 5 randomized
prospective studies, 4 demonstrate the significant efficacy
of chemical peels in reducing the AK count.8–11 Chemical
peels have demonstrated potential for chemoprevention of
future AKs and keratinocyte carcinomas while also providing cosmetic improvement.8,11 The most well-studied
peels with reduction in the AK count appear to be 30% TCA
peel and the combined Jessner’s solution and 35% TCA
peels. From a provider perspective, chemical peels are costwww.dermatologicsurgery.org
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effective by allowing treatment of large surface areas
quickly with low overhead cost. The materials for a
chemical peel are relatively inexpensive when compared
with 5-FU or a laser.
From patients’ perspectives, chemical peels were preferred to 5-FU because of single application, decreased
downtime, and minimal adverse effects.8,10 In each study,
the chemical peel was applied during a single office visit. By
contrast, treatment of AKs with 5-FU require full adherence
to once to twice daily usage for multiple weeks. Although
some studies reported patient withdrawal or severe adverse
effects to carbon dioxide laser resurfacing or PDT, patients
treated with chemical peels reported mild erythema and
discomfort.8–12 One study noted potential scarring after
35% TCA peel; however, some of these patients required at
least one additional PDT treatment 1 to 6 months after TCA
peel because of treatment failure.12
From a clinical standpoint, the authors recommend the
following “pearls” to optimize the results of chemical
peeling for field precancerization. Notably, medium depth
chemical peels should not be performed off the face and
scalp because of the risk of scar.15 Before the procedure,
patients should apply a retinoid cream (such as tretinoin
0.05% cream) to the affected areas nightly for approximately 4 weeks to enable even penetration of the peeling
solution. During the roughly 7-day recovery, regular
application of bland emollient as well as oral antiviral
(such as acyclovir) prophylaxis will minimize the risk of
postprocedure complications. In one author’s experience
(S.L.S.), organ transplant recipients on systemic retinoids
for chemoprevention of AK, such as acitretin or isotretinoin, do not require prepeel topical retinization to promote
efficient and even frost formation. Anecdotally, chemical
peels when used as field therapy seem to offer comparable
outcomes among immunocompetent and immunosuppressed patients. Another author (P.R.) uses lesiontargeted therapy with spot application of Hetter formula
phenol 33%–croton oil 0.35% to flat AKs, sometimes in
combination with gentle curettage to hyperkeratotic lesions,
in patients who are intolerant to cryotherapy. These realworld clinical experiences may be helpful in informing the
use of chemical peels in the management of AKs.
Our review is limited by the overall small number of
prospective studies with relatively small sample sizes.
Owing to the heterogeneity of peeling agents used, a metaanalysis based on the data from the systematic review was
unfeasible. The small number of included studies is partially
due to the lack of studies that performed AK counts before
and after treatments. Moreover, although chemical peels
are a known indication for treatment of AKs,15 chemical
peels may not be commonly used for field treatment of AKs.
A survey of Australian dermatologists reported the most
common indications for chemical peeling in their practices
were photoaging (87%), comedonal acne (67%), lentigines
(60%), and melasma (60%).16 Although most dermatology
residents receive didactic instruction on cosmetic dermatology, 46% of surveyed residents reported receiving hands-on
training or lectures on chemical peels.17 The comparatively

decreased usage of chemical peels for treatment of AKs
along with the overall lack of residency training on the use
of chemicals peels may further contribute to the lack of
available literature regarding this topic.
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Conclusion
Chemical peels are a well-established and well-tolerated
option for field treatment of AKs. Overall, chemical peels
were better tolerated than other field treatment options,
with similar efficacy and improved patient adherence. Its
cost-effectiveness, potential to prevent future keratinocyte
carcinoma, and acceptable side effect profile position
chemical peeling as an attractive option for dermatologists
and for their patients.
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